الفهرس 
ContentsOnly 14 pages are availabe for public view
 |  | from | 161 |  |  |
| | | from | 161 | | |
Abstract
The aim of this study was to assess the serum levels of IL-33 in SLE patients and to correlate it with systemic lupus disease activity index (SLEDAI) score and with various clinical and laboratory criteria of SLE. This study included 60 patients with SLE selected from the outpatient clinics of Rheumatology and Rehabilitation, Internal Medicine and Nephrology departments, Mansoura University Hospitals and twenty apparently healthy matched controls. SLE patients were diagnosed according to systemic lupus international collaborating clinics (SLICC), new classification criteria 2012. SLE patients underwent thorough history taking, general and systemic examinations, ECG and plain X-rays of chest and affected joints. Systemic lupus erythematosus disease activity index (SLEDAI) score was used for assessment of disease activity. Blood samples from patients and controls were collected for measurement of CBC, ESR, CRP, liver and kidney function tests CK, LDH, aldolase, serum ANA, anti-ds DNA, anti-phospholipid antibodies, complement levels C3 and C4 and IL-33 by ELISA. Urine was collected for measurement of analysis and 24-hours protein. Serum levels of IL-33 in SLE patients had been correlated with SLEDAI score and with various clinical and laboratory criteria of SLE. The main results were: Serum level of IL-33 was significantly higher in patients with SLE than that in healthy controls (P=0.003) Serum level of IL-33 was not significantly correlated with total SLEDAI score. SLE patient with high IL-33 level had 3.2 times higher risk of developing oral ulcers, and 3.8 times higher risk of developing vasculitis than patient with low IL 33 levels Other clinical and lab criteria had no significant association with serum level of IL-33. Conclusion: Our finding of elevated serum levels of IL33 in SLE patients compared to controls suggests that IL-33 plays an important role in the development and/or progression of vasculitis and mucosal ulcers in SLE patients. Therefore, elevated IL-33 levels may be considered as a good biomarker for predicting the development of vasculitis and/ or mucosal ulcers in SLE patients and this may help to modify the treatment accordingly.